ChartMill assigns a Buy % Consensus number of 69% to ARNA. The Buy consensus is the weighted average rating of the current analysts ratings.
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2022-02-09 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2021-12-21 | Cantor Fitzgerald | Downgrade | Overweight -> Neutral |
| 2021-12-14 | JMP Securities | Downgrade | Market Outperform -> Market Perform |
| 2021-12-14 | RBC Capital | Downgrade | Outperform -> Sector Perform |
| 2021-12-14 | SVB Leerink | Downgrade | Outperform -> Market Perform |
| 2021-12-14 | Credit Suisse | Downgrade | Outperform -> Neutral |
| 2021-12-14 | Citigroup | Downgrade | Buy -> Neutral |
| 2021-12-14 | Jefferies | Downgrade | Buy -> Hold |
| 2021-12-13 | Needham | Downgrade | Buy -> Hold |
| 2021-12-08 | Wells Fargo | Initiate | Overweight |
| 2021-08-10 | Cantor Fitzgerald | Maintains | Overweight |
| 2021-08-06 | Credit Suisse | Maintains | Outperform |
| 2021-05-18 | Goldman Sachs | Initiate | Buy |
| 2021-05-07 | SVB Leerink | Maintains | Outperform |
| 2021-04-27 | Citigroup | Initiate | Buy |
| 2021-04-13 | Credit Suisse | Maintains | Outperform |
| 2021-03-26 | HC Wainwright & Co. | Maintains | Buy |
| 2021-03-03 | Cantor Fitzgerald | Maintains | Overweight |
| 2021-02-24 | SVB Leerink | Maintains | Outperform |
19 analysts have analysed ARNA and the average price target is 99.8 null. This implies a price decrease of -0.19% is expected in the next year compared to the current price of 99.99.
The consensus rating for ARENA PHARMACEUTICALS INC (ARNA) is 69.4737 / 100 . This indicates that analysts generally have a neutral outlook on the stock.